Hostname: page-component-7b7567c8c-tnkh4 Total loading time: 0 Render date: 2026-11-17T10:43:51.735Z Has data issue: false hasContentIssue false

Multiple Sclerosis Treated with Antithymocyte Globulin — A Five Year Follow-Up

Published online by Cambridge University Press:  18 September 2015

L.F. Kastrukoff
Affiliation:
Department of Medicine, Division of Neurology of the University of Alberta, Edmonton
D.R. McLean*
Affiliation:
Department of Medicine, Division of Neurology of the University of Alberta, Edmonton
T.A. McPherson
Affiliation:
Division of Oncology of the University of Alberta, Edmonton
*
Division of Neurology, Department of Medicine, 9-101 Clinical Sciences Building, University of Alberta, Edmonton, Alberta, Canada T6G 2G3.
Rights & Permissions [Opens in a new window]

Summary:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

Multiple sclerosis patients treated with antithymocyte globulin (ATG) were re-evaluated after five years. No long term benefit was found. Notably, the group of patients with an elevated gamma globulin to total protein ration in their C.S.F. and who did particularly well after treatment with ATG also failed to show any long term benefit. Few long term detrimental effects of ATG immunosuppression were identified. The implications of the results are discussed as they relate to the use of immunosuppression in multiple sclerosis.

Information

Type
Research Article
Copyright
Copyright © Canadian Neurological Sciences Federation 1978